Technology Commercialization Office

Tuesday, June 23, 2015 Anne Co’s new, five-year $651,729 NSF CAREER Award for “Control of surface reactivity for catalyzing hydrocarbon formation from CO₂,” will allow her to expand her research on advanced  electrocatalytic materials for chemical conversion and energy storage. Co, assistant professor, chemistry and biochemistry; and her students, focus on fundamental studies of electrochemical reactions and electrocatalyst function. They investigate novel nanoporous electrode materials and single atomic layer model

Tuesday, June 2, 2015 | 10:00 AM – 11:00 AM |115 BRT Registration and more information is available at http://researchcalendar.osu.edu/index.php?eID=829   This presentation will provide details of the program, application process, award management process and summary of past funding rounds. An additional funding cycle with a proposal deadline in the fall of 2015 will be announced soon. Funding awards will be in the form of a grant. Up to $200,000

Sponsored by The Ohio State University Drug Development Institute and Charles River Laboratories Tuesday, April 28th 10:00am – 2:00pm Biomedical Research Tower, Room 115 460 West 12th Avenue Columbus, Ohio 43210 Ohio State’s Drug Development Institute and Charles River Laboratories are happy to announce a symposium detailing the drug discovery and development process as it is practiced in the pharmaceutical industry and in academia. The goal of this symposium is

Credit to Columbus Business First,  Paula Christian: published January 30, 2015   With so much health care research taking place here, Columbus Business First took a look at five innovations that, while in infancy now, could change patient care someday. Plenty of ideas germinated locally already have made it to market. Take the EpiGlare patented by Columbus eye surgeon Dr. Alice Epitropoulos that helps measure the vision deficits caused by

The Commercialization Workshop Series walks participants through the commercialization process in eight workshops spanning January through August. Each interactive workshop will have subject matter experts discussing the topics while referencing a technology from Ohio State that has been commercialized. Come learn about commercialization and what resources are available to aid faculty and staff in that process. Introduction to Commercialization Workshop An Introduction to Commercialization is the first of eight workshops

Every day breakthrough innovations occur at The Ohio State University and sometimes these inventions need just a small amount of capital for further development. Seeing this need for proof of concept funding, the Technology Commercialization Office, Office of Research, and TechColumbus are implementing a new funding program known as the Accelerator Awards. The Accelerator Awards will provide a small amount of fast and flexible capital to Ohio State researchers to

Ohio-based Venture Therapeutics Named Industry Partner COLUMBUS, Ohio – The Ohio State University and the University of Michigan have signed an exclusive worldwide agreement with Ohio-based Venture Therapeutics, Inc., to form a new company to develop and commercialize a pharmaceutical technology targeted for the treatment of precancerous oral lesions. These lesions are currently managed by invasive surgery and approximately a third of these lesions will reoccur after surgery. Previously published

COLUMBUS, Ohio, and MIAMI, Florida–The Ohio State University, through the Ohio State Innovation Foundation, has signed an exclusive world-wide licensing agreement with MedVax Technologies, Inc., for the licensing of groundbreaking cancer peptide vaccine technologies. The anticancer vaccine technologies are designed for the treatment and prevention of cancers associated with the HER2 protein. These include breast, ovarian, lung, colon and pancreatic cancers, and gastrointestinal stromal tumors. The commitment by MedVax will allow

Ohio State Partners with Signet Accel LLC to Accelerate Health Care Data Sharing Worldwide Agreement includes largest up-front licensing fee  COLUMBUS, Ohio – The Ohio State University today announced the signing of an exclusive worldwide agreement with a new company formed by Signet Enterprises: Signet Accel LLC. The new company will license a portfolio of cutting-edge Ohio State-developed software technologies for health care data sharing and advanced analytics through the

$1 Million Evergreen Fund to Commercialize Ohio State Technology Columbus, OH (December 19, 2013) Innovations with ties to The Ohio State University will get a financial boost from the new Technology Concept Fund, LLC. The million-dollar fund includes investments from Ohio State and Ohio Third Frontier. The Technology Concept Fund will be managed by TechColumbus. “The Technology Concept Fund will provide critical investment capital at the earliest stage and is